Kiora Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Kiora Pharmaceuticals, Inc. carries a market capitalization of 11.30M, placing it among publicly traded companies globally. Its enterprise value stands at -4.85M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.30M |
| Enterprise Value | -4.85M |
Share Statistics
Kiora Pharmaceuticals, Inc. currently has 4.43M shares outstanding.
| Shares Outstanding | 4.43M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.69 |
| P/TBV Ratio | 0.79 |
| P/FCF Ratio | -1.54 |
| P/OCF Ratio | -1.51 |
Financial Position
Kiora Pharmaceuticals, Inc. maintains a current ratio of 8.97, meaning it holds 9.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.97 |
| Quick Ratio | 8.33 |
| Debt / Equity | 1.98 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -56.36 |
| Return on Assets (ROA) | -39.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.29M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Kiora Pharmaceuticals, Inc.'s stock has declined approximately -4.85075% over the past 52 weeks. The 50-day moving average sits at 2.57, while the 200-day moving average is 2.33.
| Beta (5Y) | N/A |
| 52-Week Price Change | -4.85075% |
| 50-Day Moving Average | 2.57 |
| 200-Day Moving Average | 2.33 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.73M, while operating income came in at -9.77M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -9.77M |
| Pretax Income | -12.28M |
| Net Income | -10.99M |
| EBITDA | -9.73M |
| EBIT | -9.77M |
| Earnings Per Share (EPS) | -2.24 |
Balance Sheet
Kiora Pharmaceuticals, Inc. holds 16.84M in cash and equivalents against 333,022.00 in total debt, resulting in a net debt position of -7.08M. Total book value stands at 16.86M, with working capital of 18.89M providing operational flexibility.
| Cash & Cash Equivalents | 16.84M |
| Total Debt | 333,022.00 |
| Net Debt | -7.08M |
| Equity (Book Value) | 16.86M |
| Book Value Per Share | 3.80 |
| Working Capital | 18.89M |
Cash Flow
Kiora Pharmaceuticals, Inc. produced -8.51M in operating cash flow over the past twelve months. After subtracting -107,068.00 in capital expenditures, free cash flow totaled -8.61M - equivalent to -1.76 per share.
| Operating Cash Flow | -8.51M |
| Capital Expenditures | -107,068.00 |
| Free Cash Flow | -8.61M |
| FCF Per Share | -1.76 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -42.20 |
| FCF Yield | -65.12 |
Stock Splits
Kiora Pharmaceuticals, Inc.'s most recent stock split took place on June 11, 2024 with a 9:1 split ratio.
| Last Split Date | 6/11/2024 |
| Split Ratio | 9:1 |
Scores
Kiora Pharmaceuticals, Inc. posts an Altman Z-Score of -9.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -9.66 |